Seth Porter
Vice President
Fibrosis Therapeutics
Fibrogen
China
Biography
Dr. Porter, Vice President, Fibrosis Therapeutics, joined FibroGen in 2005, and has been leading the pamrevlumab development program since 2007. He brings more than 25 years of clinical and preclinical experience in research, drug development, bioanalytics, and project development across multiple therapeutic areas. Prior to joining FibroGen, Dr. Porter held several research and development positions in pharmaceutical and biotechnology companies in the San Francisco Bay Area, including Adamas Pharmaceuticals, Cerus Corporation, Genentech, Syntex Laboratories (now Roche) and Athena Neurosciences (acquired by Elan Pharmaceuticals plc). He received a Ph.D. in Biochemistry from Dartmouth Medical School in 1984 and completed his post-doctoral training in Biochemistry and Neurobiology at Washington University Medical School.
Research Interest
Biochemistry, Molecular Biology
